The Chase Group Secures VP, Head of Regulatory Affairs, for Checkmate Pharmaceuticals

Checkmate Pharmaceuticals Logo The Chase Group is pleased to announce the successful recruitment of Elvis Osei Tutu, PharmD, as the Vice President, Head of Regulatory Affairs at Checkmate Pharmaceuticals. Dr. Osei Tutu brings valuable regulatory experience in the immune-oncology landscape to the team at Checkmate as they keep their focus on important regulatory milestones for vidutolimod. This hands-on role gives Dr. Osei Tutu responsibility for the development and execution of Checkmate’s global regulatory strategy as the team’s regulatory expert. Checkmate Pharmaceuticals is a clinical-stage biotechnology company focused on developing its proprietary technology to harness the power of the immune system to combat cancer. Checkmate is investigating their lead candidate, vidutolimod, across multiple tumor types in combination with checkpoint inhibitor immunotherapies in melanoma and non-melanoma skin cancers and head and neck cancer. A growing body of promising clinical data demonstrates its potential to address the unmet need for patients whose cancers are resistant to immunotherapeutic agents. Dr. Osei Tutu joins a team of scientists, physicians, and life sciences entrepreneurs who are dedicated to discovering and developing new approaches to fighting cancer. The Chase Group is proud to partner with Checkmate and contribute to their success as they work to harness the power of the immune system to combat cancer. For more information on partnering with The Chase Group to identify & secure executive leadership for your organization contact moira@chasegroup.com
  • Categories: Life Sciences

Copyright © 1993-2024 The Chase Group. All Rights Reserved.